Amgen Inc. (AMGN) Cash Flow Statement

The wide quarterly swings in OCF/NI, from 7.61 in Q4 2024 to -6.10 in Q1 2024, suggest that net income is not a reliable proxy for cash generation on a quarter-by-quarter basis. The positive working capital contributions in Q2 2026 and Q3 2025 likely reflect favorable collections or inventory management, but the negative swings in other quarters highlight the lumpy nature of the business. Investors should focus on annualized cash conversion rather than quarterly noise.

The sequential improvement in FCF from $1.5B in Q1 2026 to $3.5B in Q2 2026, despite a modest increase in capex, indicates strong operating leverage. The FCF margin of 34.7% in Q2 2026 is well above the 10-quarter average, suggesting that the recent EPS beat was supported by genuine cash generation. However, the trajectory is volatile, with Q4 2025 FCF margin dipping to 9.7%, so sustainability of this level warrants monitoring.

The absolute CapEx of $513M in Q2 2026 is the highest in the last four quarters, suggesting that Amgen is investing in manufacturing capacity or pipeline assets. However, the capital intensity remains low relative to the company's revenue base, which supports high FCF margins. The increase may reflect growth-oriented spending, but the company's high fixed-cost base suggests that maintenance capex is a significant component, and investors should monitor whether this trend continues.

The alternating positive and negative working capital contributions across quarters suggest that Amgen's cash conversion cycle is subject to significant seasonal or deal-related fluctuations. The large positive contribution in Q4 2024 ($2.1B) and Q3 2025 ($1.7B) may reflect year-end collections or inventory reductions, while the negative contributions in Q1 2025 and Q4 2025 indicate build-ups. This pattern implies that management has limited control over the timing of cash flows, and investors should adjust for these swings when assessing underlying performance.

With no buybacks in most quarters and dividends consistently around $1.2-1.4B, Amgen's capital deployment is heavily skewed toward shareholder income. The absence of buybacks, despite a high debt load, suggests that management is prioritizing debt reduction or maintaining liquidity. However, the dividend payout ratio relative to FCF is manageable, but the company's ability to service its debt while maintaining the dividend will depend on sustaining the recent FCF improvement.

The cumulative gap between net income and operating cash flow is positive, suggesting that Amgen's earnings quality is high, but the quarterly volatility in OCF/NI indicates that accruals and working capital adjustments can distort short-term comparisons. The large positive gap in Q4 2024 (OCF/NI of 7.61) was likely driven by non-cash items or working capital releases, while the negative gap in Q1 2024 reflects a net loss. Over a longer horizon, the cumulative cash generation appears robust, but the inconsistency warrants caution in using net income as a sole indicator of cash flow strength.